Business Wire

Philips Launches Brand-New Version of SpeechLive Speech-to-Text Solution

Del

Speech Processing Solutions, the world number one in professional dictation, has launched a brand new version of their Philips SpeechLive dictation and speech recognition workflow solution. The cloud-based solution saves busy professionals’ time and resources by allowing them to be more flexible and turn their voice into written documents quicker than ever before. The latest version of the solution comes with improved usability, new features and enhanced stability for an even more efficient dictation workflow.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171205005110/en/

Philips SpeechLive (Photo: Business Wire)

Philips SpeechLive (Photo: Business Wire)

New SpeechLive Upload Client

The enhanced upload client automatically feeds audio files from dictation recorders straight into the SpeechLive system. The new feature works on Windows computers with all Philips devices including the Philips Pocket Memo, SpeechAir and Voice Tracers. Even customers using non-Philips audio recording devices can take advantage of this time-saving innovation. Users only need to simply plug in their dictation recorder to their PC and the files will transmit automatically.

Email notification for transcriptionists

Another new feature of SpeechLive 8.5 is that transcriptionists receive automatic email notifications whenever new dictations arrive in their SpeechLive intray. This way transcriptionists can attend to important tasks quicker than before. “We wanted to improve the workflow capabilities for our users, to enable them to get their tasks done even quicker than before” explains Dr Thomas Brauner, CEO of Speech Processing Solutions.

Transcription and speech recognition service

Philips SpeechLive offers two additional productivity-boosting services to their users: Philips Speech Recognition Service and Philips Transcription Service. “The transcription service is perfect for when your assistant or transcriptionist is out of the office or simply too busy. Our highly trained transcriptionist staff will take care of even complex transcriptions for you and deliver them back to you quickly” adds Dr Brauner.

Free trial with free included speech recognition minutes

Philips provides a completely free 30-day trial of SpeechLive, where customers can test the solution themselves. The free trial includes 10 free speech recognition as well as 10 free transcription service minutes, so users can test these two additional services as well.

Visit www.speechlive.com to sign up for a free trial now.

About Speech Processing Solutions

Speech Processing Solutions is the global number one in professional dictation solutions. Founded in Austria in 1954 as part of Philips, the company has been the driving force behind innovative speech-to-text solutions for over 60 years. The company has developed ground-breaking products, such as the mobile Philips SpeechAir device, the Philips PocketMemo voice recorder, the Philips SpeechMike Premium USB dictation microphone and the Philips voice recorder app for smartphones, thus delivering its promise of excellence and outstanding quality. Thanks to the latest innovation, Philips SpeechLive, designed as a cloud-based workflow solution, recording dictations is quicker and easier than ever. The tailored range of products and services offered by Speech Processing Solutions helps professional users to save time and resources and to work at maximum efficiency.

Follow Speech Processing Solutions:

Facebook: http://www.facebook.com/philipsvoicetracer

Instagram: https://www.instagram.com/philips_dictation/

Twitter @speech_com: http://www.twitter.com/speech_com

YouTube: http://www.youtube.com/philipsdictation

LinkedIn: http://www.linkedin.com/company/speech-processing-solutions

Contact information

Your contact for further information:
Speech Processing Solutions
Lea Pachta
lea.pachta@speech.com
Tel: +43 160529-1744
www.philips.com/dictation

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Lehman Brothers Treasury Announces Plans for Partial Wind-Down14.12.2018 17:41Pressemelding

Lehman Brothers Treasury Co. B.V. in liquidation (“LBT”) today, through its U.S. counsel Kramer Levin Naftalis & Frankel LLP, announced that LBT is planning a final cash distribution to its creditors. Professional holders of eligible notes will have the option to retain their investment by electing to receive substitute notes of one (or a few) series. Such election shall take place through a solicitation process. As a consequence, LBT will be able to reduce the number of series of notes outstanding from more than 3,700 to one or a few. Noteholders electing to receive substitute notes will be afforded the same economic entitlement to distributions received by LBT from Lehman Brothers Holdings Inc. (“LBHI”) through the substitute notes. The substitute notes will be denominated in U.S. dollars and future distributions will be made in U.S. dollars only. Noteholders who are not professional investors, or hold notes that are not eligible for substitution, or do not elect to receive substitut

Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Combination with AVD14.12.2018 17:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the extension of the marketing authorization of ADCETRIS (brentuximab vedotin) and recommended its approval in combination with AVD in adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma. ADCETRIS is an antibody-drug conjugate (ADC) directed at CD30, a defining marker of Hodgkin lymphoma. ADCETRIS is currently not approved as a therapy for previously untreated Hodgkin lymphoma in Europe. “For a large number of previously untreated Hodgkin lymphoma patients diagnosed with Stage IV disease, progression will occur with current treatments, highlighting a true unmet need in this population,” said Anna Sureda, M.D., Ph.D., Head of the Hematology Department and Hematopoietic Stem Cell Transplant Programme, Institut Català d'Oncologia - Hospital Duran i Reynals. “In the ECHELON-1 cl

Diamond CBD, POTN Subsidiary, Enters the $46 Billion Coffee Market With the Release of Premium Line of CBD-Infused Coffee & Tea K-Kup Capsules14.12.2018 15:42Pressemelding

Diamond CBD Inc., wholly owned subsidiary of PotNetwork Holdings, Inc. (OTC Pink: POTN), a leader in hemp extraction and innovative CBD products for the wellness market, enters the Coffee segment, an industry expected to reach revenues of $46 Billion in 2018. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181214005308/en/ Experience a cup of Chill (Photo: Business Wire) Produced in accordance with a universal K-Cup design, these pods fit in almost all modern single cup coffee makers, making it an easily integrated enhancement to any environment, delivering 25mgs of CBD in a tasty favorite beverage at less than $5 per cup. This new line of premium Chill Coffee Capsules was recently added to the Company’s broad range of cannabinoid and natural hemp products. Each box comes with 4 individual capsules in original chill coffee, decaf chill coffee, chill black tea, and chill green tea flavors. The unit price for each box is $10.00

Henley & Partners Enlarges Executive Committee to Manage Expansion and Growth14.12.2018 14:00Pressemelding

Residence- and citizenship-by-investment programs have firmly established themselves over the past few years as the new frontier in terms of freedom, flexibility, and future-readiness, both for the countries issuing these programs and for the individual investors participating in them. The societal and economic value these programs generate is undisputed. The investment migration industry as a whole is currently grossing roughly USD 18 billion per year, with an expectation that it will hit the USD 20 billion mark very soon. Foreign direct investment (FDI) is now considered the lifeblood of economic growth for many developing and recovering smaller countries around the world. As such, the number of investment migration programs has been increasing rapidly, from just a handful of programs in the 1980s and 1990s to over 100 countries that now have investment migration provisions in their laws. There are more than 60 active programs today, with Moldova and Montenegro — both fast-growing Eu

Vargatef® plus docetaxel could be an option after failure of immunotherapy in lung cancer14.12.2018 09:07Pressemelding

Boehringer Ingelheim announced today the first interim results of VARGADO, an ongoing non-interventional study in routine clinical practice in Germany evaluating the efficacy and safety of Vargatef® (nintedanib) and docetaxel in patients with stage III/IV locally advanced or metastatic non-small cell lung cancer (NSCLC) of adenocarcinoma histology. The study consists of three cohorts, two of which allow for prior treatment with immune checkpoint inhibitors (ICIs) either in combination with chemotherapy in the first-line or as monotherapy in the second-line of treatment. The interim results from Cohort B (first-line chemotherapy, second-line immune checkpoint inhibitors, third-line Vargatef® plus docetaxel) were presented today at ESMO Immuno-Oncology Congress 2018 in Geneva.1 Despite a limited sample size, the VARGADO study adds to the body of evidence for nintedanib in lung adenocarcinoma following pre-treatment with chemotherapy and ICIs.1,3 The addition of nintedanib to docetaxel ha

Alps Electric to Exhibit at CES 2019 as Alps Alpine for the First Time14.12.2018 07:58Pressemelding

Japanese comprehensive electronic components manufacturer Alps Electric Co., Ltd. (TOKYO:6770) (Ota-ku, Tokyo; President: Toshihiro Kuriyama) will exhibit at CES 2019, to open at the Las Vegas Convention and World Trade Center in Las Vegas, Nevada, in the United States on January 8. Alps Electric will be taking part as a new company, Alps Alpine Co., Ltd., for the first time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181213006022/en/ Alps Alpine's new touch input device for automotive (Graphic: Business Wire) At CES 2019, an exposition of cutting-edge technologies brought together from around the world, Alps Electric will present a variety of technologies in response to the major trends in automotive development referred to as “CASE”—namely connected cars, autonomous driving, sharing and services, and electric vehicles. Making its first appearance at the show as a new company following its business integration with subs